FAPI, F-DOPA & Newer Tracers
Which PET Tracer — Do You Actually Need?
Not all PET scans use the same tracer. The tracer is chosen based on your cancer type — and using the wrong one can miss disease that the right one would have found.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed September 2026
- FDG is not always enough — FDG works by detecting glucose use. Several cancers — including prostate, neuroendocrine tumours and some brain tumours — are not reliably visible on an FDG scan.
- Each tracer has a specific target — PSMA targets a protein on prostate cancer cells. DOTATATE targets receptors on neuroendocrine tumours. FAPI targets the cells that surround most solid tumours.
- Newer is not always better — FAPI and some other newer tracers are emerging rather than established. Evidence is growing, but your oncologist will tell you whether there is a clear indication for your cancer.
- Your oncologist decides — The tracer is chosen based on your cancer type, stage, and what the scan needs to answer. You can — and should — ask why a particular tracer was chosen.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Your oncologist chooses the tracer based on your cancer type and what question the scan needs to answer. FDG is the starting point for most cancers but misses several. PSMA is for prostate, DOTATATE for neuroendocrine tumours, and newer tracers like FAPI and F-DOPA find what the standard scan cannot.
CION does PET-CT in Hyderabad from Rs 10,499 — among the lowest published prices in the city, with no hidden charges. Indicative price, as of September 2026.
Which tracer is used for which cancer?
| Tracer | Main cancers | What makes it different from FDG | Evidence status |
|---|---|---|---|
| FDG | Lung, breast, lymphoma, colorectal, head and neck, and many others | The default — covers the widest range of cancer types | Established standard of care (NCCN, ESMO, ICMR) |
| PSMA (Ga-68 or F-18) | Prostate cancer | Detects recurrence at very low PSA; finds lymph node spread too small for CT | Established — NCCN and ESMO endorsed |
| DOTATATE (Ga-68) | Neuroendocrine tumours: carcinoid, pancreatic NET, phaeochromocytoma | Targets somatostatin receptors — finds tumours that do not take up glucose | Established — NCCN and ESMO endorsed |
| F-DOPA (F-18) | Neuroendocrine tumours, paraganglioma, insulinoma, glioma | Detects dopamine-producing tumours and brain tumours with low FDG uptake | Established for these specific indications |
| FAPI (F-18 or Ga-68) | Gastric, pancreatic, cholangiocarcinoma, peritoneal disease | Targets tumour-surrounding tissue; may detect peritoneal spread FDG misses | Emerging — promising evidence, not yet standard of care for most cancers |
How does your oncologist choose which tracer to use?
The choice starts with your cancer type. For prostate cancer, PSMA is now preferred over FDG in most situations. For neuroendocrine tumours, DOTATATE is the standard choice. When the diagnosis is one of these, your oncologist is not weighing options — there is a clearly supported answer.
The second factor is what question the scan needs to answer. Staging at diagnosis, detecting a suspected recurrence, and checking whether treatment is working can each call for a different tracer, even in the same person.
Availability matters too. Your oncologist will direct you to a partner imaging centre that has the specific tracer your scan needs. Not every tracer is produced at every centre.
Which cancers most often need a tracer other than FDG?
Prostate cancer is the clearest example. FDG scans frequently show nothing in prostate cancer, especially when PSA is low. PSMA PET is now the preferred approach for staging and detecting recurrence, endorsed by NCCN and ESMO.
Neuroendocrine tumours — including carcinoid tumours and pancreatic NETs — are another group where FDG regularly misses disease that DOTATATE is designed to find.
Certain gastric, pancreatic and bile duct cancers are candidates for FAPI scanning, particularly when FDG has been inconclusive or when peritoneal spread is suspected. The evidence here is still developing, and your oncologist will tell you whether it applies to your situation.
PET-CT Partner Centres
PET-CT Scan Centres in Hyderabad
CION offers PET-CT scans through 4 trusted partner PET-CT centres across Hyderabad, so you can choose the one closest to you. Call 18002028726 and we’ll guide you to the earliest available appointment.
PET-CT Centre — Punjagutta
PET-CT Centre — Himayatnagar
PET-CT Centre — Narayanaguda
These are partner diagnostic centres within the CION network. Toll-free booking: 18002028726.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Who decides — and can you ask for a newer tracer?
Your oncologist decides which tracer is appropriate. This is a clinical decision based on your diagnosis, stage, and what the scan needs to answer. You should feel free to ask which tracer has been requested and why, and whether it has established guideline support for your cancer type.
If a newer tracer such as FAPI has been requested, ask for the reason. The answer will usually be that FDG was inconclusive, or that your cancer type is one where FAPI is currently being studied and used where standard options have not given a clear picture.
Specialised tracers — PSMA, DOTATATE, F-DOPA and FAPI — are available through CION partner imaging centres. At the time this page was written, the indicative cost was around ₹23,999; confirm the current figure when you book, as costs change.
What do these tracer names actually mean?
- FDG
- F-18 fluorodeoxyglucose. A radioactive form of glucose. Most tumours consume glucose faster than normal tissue, which makes them visible on the PET scan.
- PSMA
- Prostate-specific membrane antigen. A protein found in large numbers on prostate cancer cells. The tracer attaches to this protein to make the cells visible on the scan.
- DOTATATE
- A tracer that attaches to somatostatin receptors. Neuroendocrine tumours carry large numbers of these receptors, which is why DOTATATE is designed to find them when FDG cannot.
- F-DOPA
- A tracer based on a precursor of dopamine. Used for tumours that produce dopamine-related chemicals, including certain brain tumours, insulinoma and paraganglioma.
- FAPI
- Fibroblast activation protein inhibitor. A newer tracer targeting cells that surround solid tumours rather than the tumour cells themselves. Evidence is growing but not yet at guideline level for most cancers.
- Established use
- An indication supported by guidelines from NCCN, ESMO, ASCO or ICMR. Your oncologist can request it with confidence based on that body of evidence.
- Emerging use
- An indication where early evidence is promising but large trials are not yet complete. Your oncologist will tell you whether using it in your situation is appropriate.
What should you ask before your PET scan is booked?
- Ask your oncologist which tracer has been requested and why.
- Ask whether the tracer has established guideline support for your cancer type, or whether it is being used because FDG was inconclusive.
- Tell the imaging team about all medications, supplements, insulin and any ayurvedic or herbal preparations you are taking.
- If you have diabetes, ask how to manage your blood sugar the night before and the morning of the scan.
- Ask what specific question the scan is designed to answer — staging, recurrence, or treatment response.
- If a specialised tracer has been requested, confirm it is available at the partner centre before you travel.
CION does PET-CT in Hyderabad from Rs 10,499 — among the lowest published prices in the city — including an oncologist-reviewed report and a free Rs 950 consultation. Indicative price, as of September 2026.
Explore 72 more Specialised Tracers and How PET-CT Compares topics
FAPI, F-DOPA & Newer Tracers
- Amyloid and Tau PET for Dementia
- Can You Choose Your Own Tracer?
- Choline and Fluciclovine PET for Prostate Cancer
- F-18 NaF Bone PET: A Better Bone Scan?
- F-DOPA PET-CT: Uses in Parkinson's and Paraganglioma
- FAPI PET-CT Cost in Hyderabad
- FAPI PET-CT: The Tracer That Finds What FDG Misses
- FAPI vs FDG: When the Newer Tracer Is Better
- FES PET for Hormone-Receptor Breast Cancer
- MIBG Scan vs DOTA PET: Which for Neuroendocrine Disease?
- New PET Tracers Coming to India
- Tracer Availability and Why Your Scan Date Is Fixed
- Which PET Tracer Do You Actually Need?
- Why Specialised Tracers Cost More Than FDG
DOTANOC & DOTATATE PET-CT
- DOTA PET and PRRT (Lu-177 DOTATATE) Therapy
- DOTANOC and DOTATATE PET-CT: What They Are
- DOTANOC vs DOTATATE: Is There a Difference?
- DOTATATE PET-CT Cost in Hyderabad
- False Positives on DOTA PET Scans
- Is DOTA PET Covered by Insurance in India?
- Is DOTATATE PET Available in Hyderabad?
- Preparing for a DOTANOC or DOTATATE Scan
- Reading a DOTA PET Report
- The Krenning Score on Your DOTA PET Report
- When Is a DOTA PET Scan Ordered?
- Why Do I Need Both a DOTA PET and an FDG PET?
PET-CT vs Other Scans
- Can an MRI Replace a PET-CT to Avoid Radiation?
- Choosing Between Scans: A Decision Guide by Question
- Combining PET-CT With MRI in the Same Week
- Diagnostic CT vs the CT Inside a PET-CT
- Do You Need Both a CT and a PET-CT?
- Follow-Up Scanning: Alternating PET With Other Tests
- PET-CT vs Biopsy: Which Actually Diagnoses Cancer?
- PET-CT vs Bone Scan for Bone Metastases
- PET-CT vs CT Scan: What Is the Difference?
- PET-CT vs MRI: Which Do You Need?
- PET-CT vs PET-MRI: Is the Newer Machine Better?
- PET-CT vs Tumour Markers for Follow-Up
- PET-CT vs Ultrasound and Mammography
- PET-CT vs Whole-Body MRI for Screening
- When Is a PET-CT Not the Right Test?
- Why Your Doctor Ordered PET-CT and Not a Cheaper Scan
PSMA PET-CT
- False Positives on PSMA PET
- Is PSMA PET Available in Hyderabad and How Soon?
- Is PSMA PET Covered by Insurance or Aarogyasri?
- PSMA PET Before Prostate Surgery or Radiation
- PSMA PET and Lu-177 PSMA Therapy: The Link
- PSMA PET for Cancers Other Than Prostate
- PSMA PET vs Bone Scan and MRI for Prostate Cancer
- PSMA PET vs Normal FDG PET for Prostate Cancer
- PSMA PET-CT Scan Cost in Hyderabad
- PSMA PET-CT: What It Is and Who Needs It
- PSMA-Avid Lesions: What the Report Means
- Preparing for a PSMA PET-CT Scan
- Reading a PSMA PET Report: PRIMARY and miTNM
- Repeat PSMA Scans: How Often and Why
- Rising PSA With a Negative PSMA Scan: What Now?
- When Should You Get a PSMA PET Scan?
Timing Around Treatment
- Baseline PET-CT Before Starting Treatment: Why It Matters
- Can a PET-CT Be Done During Active Chemotherapy?
- Emergency and Urgent PET-CT: When It Cannot Wait
- How Soon After a Previous PET Can You Have Another?
- Interim vs End-of-Treatment Scanning
- PET-CT After Growth Factor Injections
- PET-CT After Steroids: Does It Affect the Scan?
- PET-CT After a Biopsy: How Long to Wait
- PET-CT Before Surgery: What Surgeons Want to Know
- Scanning Too Early: Why It Wastes Money and Causes Panic
- When Should You Have a PET-CT After Chemotherapy?
- When Should You Have a PET-CT After Immunotherapy?
- When Should You Have a PET-CT After Radiotherapy?
- When Should You Have a PET-CT After Surgery?
Your next step
Talk to an oncologist about your scan
Your PET-CT report read by a senior oncologist, explained in plain language, with a free 45-minute consultation.
Common questions
Frequently asked questions
Is FDG always the first PET scan I will have?
FDG is the default for most cancer types, but not all. For prostate cancer, PSMA is now preferred over FDG at most centres and is the first scan requested rather than a fallback. For neuroendocrine tumours, DOTATATE is usually arranged from the start. Your oncologist will specify which tracer is appropriate for your diagnosis — if you are unsure which one has been arranged, it is a straightforward question to ask when the scan is booked.
Why is PSMA preferred over FDG for prostate cancer?
Prostate cancer cells do not consume glucose in a way that FDG reliably detects, particularly when PSA is low. PSMA attaches to a protein that prostate cancer cells carry in large numbers, making it far more sensitive for detecting recurrence and lymph node spread at low PSA values. NCCN and ESMO now recommend PSMA over FDG for most prostate cancer staging and restaging. FDG still has a role in high-grade or treatment-resistant prostate cancer, where your oncologist will advise.
What is FAPI scanning and is it available in Hyderabad?
FAPI is a newer tracer that targets cells surrounding solid tumours rather than the tumour cells themselves. It is being studied in cancers where glucose uptake is low — including some gastric, pancreatic and bile duct cancers — and may identify peritoneal spread that FDG does not show. It is available through CION partner imaging centres. The evidence is still developing and FAPI is not yet standard of care for most cancers. Your oncologist will tell you whether there is a clear indication in your case.
Can I ask for a specific tracer, or does my oncologist decide?
Your oncologist decides, and that is the right arrangement. The tracer has to match your cancer type and the clinical question the scan needs to answer. Choosing the wrong tracer does not just mean a less useful result — it can mean missing disease that the right tracer would have been designed to find. You can and should ask which tracer has been requested and whether it has established evidence for your diagnosis. That is a reasonable question and your team should welcome it.
How long does a PET scan with a specialised tracer take?
The time depends on the specific tracer. Most PET scans involve an injection followed by a waiting period before the scan itself, and the total time at the centre is typically two to three hours including preparation. DOTATATE and PSMA scans follow a similar pattern to an FDG scan. Your imaging centre will give you exact instructions when you book — including how long to fast, when to arrive, and any blood sugar management needed if you have diabetes.
If an FDG PET scan shows nothing, does that mean there is no cancer?
Not necessarily. FDG can miss cancers that do not consume glucose readily — prostate cancer, well-differentiated neuroendocrine tumours, insulinoma and some brain tumours are the most common examples. A clear FDG result in these settings means the disease is not visible by that method, not that it is absent. This is exactly when a specialised tracer such as PSMA, DOTATATE or F-DOPA may add useful information. Share the result with your oncologist and ask directly whether a different tracer is worth considering.